The vaccine, called Arexvy, is approved for prevention of lower respiratory tract disease caused by RSV. Lower respiratory tract disease can affect the lungs and be life-threatening if it progresses to pneumonia bronchiolitis, and every year, RSV leads to about 60,000 to 120,000 hospitalizations and 6,000 to 10,000 deaths among older adults, the FDA said.
In a phase 3 study, the vaccine reduced the risk of developing the disease by 82.6 percent and lowered the risk of developing a severe form of the disease by 94.1 percent.
GSK said the product will be ready for the 2023-24 RSV season.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
